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Pneumonia and Myocardial Infarction:
Is Platelet Activation the Missing Link?*Carlos G. Santos-Gallego, MD, Juan J. Badimon, PHDC ommunity-acquired pneumonia (CAP) af-fects >5 million adults, causes 1.1 millionhospital admissions, and is responsible for
>60,000 deaths each year in the United States (1).
Recent studies connected CAP with cardiovascular
disease (CVD), the leading cause of death worldwide
(2), and its most feared complication, myocardial
infarction (MI). In this issue of the Journal, Cangemi
et al. (3) add a new piece to the puzzle of this
relationship.SEE PAGE 1917Although traditionally regarded as conﬁned to the
lungs, all severities of acute pneumonia infection
affect the cardiovascular system. Several recent
retrospective clinical observations and meta-analyses
found increased MI incidence after CAP (see Corrales-
Medina et al. [1] for a comprehensive summary).
Analysis of a prospective multicenter cohort of 2,344
unselected patients with CAP conﬁrmed these data
(4). In this cohort, 30-day incidences of heart failure,
arrhythmia, and MI were 21%, 10%, and 3%, respec-
tively, with risks peaking in the ﬁrst 2 days of hospi-
talization. Even after adjusting for baseline risk, MI
was independently associated with a 60% increase in
short-term mortality risk. These ﬁndings suggest that
prevention of cardiac complications may improve
CAP outcomes.
This increased MI risk is not limited to CAP.
Large retrospective epidemiological studies found in-
creased MI risk after acute respiratory infections (5),*Editorials published in the Journal of the American College of Cardiology
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contents of this paper to disclose.and retrospective studies (6) and clinical trials (7)
showed an association between inﬂuenza vaccina-
tion and reduced risk for MI and stroke. Additionally,
early treatment of inﬂuenza in patients with CVD
was associated with a 60% decrease in MI risk (8).
Despite this robust association, its potential
mechanisms of action are not well understood, al-
though several hypotheses have been postulated.
Atherosclerosis is an inﬂammatory disease; acute
infections, such as CAP, not only elicit systemic
inﬂammatory responses but can also have direct
inﬂammatory effects on atherosclerotic plaques, in-
creasing their vulnerability. In atherosclerotic apoli-
poprotein E–knockout mice, inﬂuenza virus infection
promotes acute inﬂammation in the atheromata
(inﬁltration of plaques with macrophages and
T lymphocytes) and superimposed ﬁbrin deposition,
similar to unstable plaques after MI (9). Coronary ar-
tery tone abnormalities may also be involved, as
increased vasoconstrictive responses were observed
in animals injected with staphylococcal a-toxins (10).
Other factors may likely contribute: tachycardia
shortens diastole (when coronary perfusion occurs),
decreased central blood pressure (as in severe sepsis)
impairs myocardial perfusion through stenotic coro-
nary segments, and hypoxemia and increased cardiac
metabolic demands (secondary to tachycardia and
catecholamine release) can contribute to the devel-
opment of myocardial ischemia.
The work of Cangemi et al. (3) is a prospective study
in which 278 consecutive patients with CAP at
4 different hospitals were recruited and followed until
discharge, including periodic cardiac (high-sensitivity
cardiac troponin T [hs-cTnT]) and in vivo platelet
activation marker measurement. Although up to 52%
of patients with CAP had high hs-cTnT levels, 11%
of them showed signs of MI (increased hs-cTnT
concentrations and electrocardiographic changes or
symptoms). Thus, in the 41% of patients without
J A C C V O L . 6 4 , N O . 1 8 , 2 0 1 4 Santos-Gallego and Badimon
N O V E M B E R 4 , 2 0 1 4 : 1 9 2 6 – 8 Pneumonia, AMI, and Platelet Activation
1927electrocardiographic changes, increased hs-cTnT is
probably not secondary to ischemia. Other possibil-
ities include stress-induced cardiomyopathy or
nonspeciﬁc toxic effects on cardiomyocytes, leading
to biomarker leakage. The 11% MI rate was higher
than in previous reports, probably explained by the
use of hs-cTnT instead of creatine kinase (4), a less
sensitive myocardial injury biomarker, and because
hs-cTnT levels were measured every 12 h, not only
at hospital admission (4). The main clinical take-
home message is that patients with previous CVD
or severe CAP (both independently associated with
MI) should be monitored daily with hs-cTnT and
electrocardiographic assessment to detect MI, espe-
cially during the ﬁrst 2 days of hospitalization,
because MI was asymptomatic and increased the risk
for death.
This paper’s importance stems from its suggestion
that high platelet activation may provide a mecha-
nistic explanation for increased MI risk in CAP. In vivo
platelet activation markers (soluble CD40 ligand,
soluble P-selectin, and thromboxane B2 levels) at
admission were increased in patients who subse-
quently developed MIs, suggesting that CAP increases
platelet activation, which may in turn cause MI.
Previous studies highlighted the contribution of
infection to platelet activation. Kreutz et al. (11) found
increased platelet reactivity in patients affected by
viral respiratory infections compared with healthy
controls. Modica et al. (12) found more pronounced
platelet aggregation and increased aspirin non-
responsiveness in patients with MIs with concurrent
infection than in uninfected patients with MIs.
Several mechanisms were proposed to explain these
ﬁndings. Gram-positive bacteria induce platelet
aggregation and the formation of platelet-neutrophil
complexes (13). Additionally, in response to lipo-
polysaccharide from Gram-negative bacteria, plate-
lets bind more avidly to ﬁbrinogen under ﬂow
conditions in a Toll-like receptor 4–dependent
manner (14). Surprisingly, Cangemi et al. (3) found no
difference in the MI rate between aspirin-treated and
untreated patients.
A limitation of the present study is that the role of
platelet function is not fully understood. Platelet ag-
gregation may be either a risk factor (it correlates with
the disease, and treatment reduces the incidence ofthe disease) or a risk marker (it correlates with the
disease, but treatment does not affect the incidence
of the disease because it is merely a surrogate indi-
cator of disease severity). Platelet aggregation seems
to behave as a risk marker. In the GRAVITAS (Gauging
Responsiveness With a VerifyNow Assay—Impact on
Thrombosis and Safety) (15) and ARCTIC (Double
Randomization of a Monitoring Adjusted Antiplatelet
Treatment Versus a Common Antiplatelet Treat-
ment for DES Implantation, and Interruption Versus
Continuation of Double Antiplatelet Therapy;
NCT00827411) (16) clinical trials, tailored pharmaco-
logical antiplatelet therapy aiming to decrease
platelet aggregation did not reduce CVD events.
Therefore, increased platelet activation in CAP may
be a marker of disease severity but not a causal link,
and antiplatelet therapy would not reduce MI. That
aspirin-treated patients did not show reduced MI
risk in this population supports this notion, as does
the lack of a statistically signiﬁcant reduction in
MI among aspirin-treated patients with CAP in pre-
vious observational studies (17,18). Alternatively,
because platelet aggregation involves many different
agonists (arachidonic acid/thromboxane A2 receptors,
adenosine diphosphate/P2Y12 receptors, von Wille-
brand factor/glycoprotein Ib, collagen/glycoprotein
VI, glycoprotein IIb/IIIa, thrombin/thrombin recep-
tor), speciﬁc inhibition of a single pathway (throm-
boxane A2, with aspirin) may be insufﬁcient to
mitigate MI risk. An open question is whether pa-
tients with CAP should be treated prophylactically
with more potent antiplatelet therapy.
The study by Cangemi et al. (3) conﬁrms high
MI incidence during CAP (silent MI in the ﬁrst 2 days
of hospitalization, especially in patients with severe
CAP or previous CVD) and suggests CAP-mediated
increased platelet activation as the mechanistic
explanation but still leaves some questions unan-
swered. Future studies are needed for conﬁrmation
of the mechanism and to delineate the best therapy
(e.g., antiplatelet agents, vaccines) to reduce MI risk.
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